These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 10796704

  • 1. Pergolide for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M.
    Cochrane Database Syst Rev; 2000; (2):CD000235. PubMed ID: 10796704
    [Abstract] [Full Text] [Related]

  • 2. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    Clarke C E, Speller J M.
    Cochrane Database Syst Rev; 2000; (2):CD000236. PubMed ID: 10796705
    [Abstract] [Full Text] [Related]

  • 3. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE, Deane KH.
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [Abstract] [Full Text] [Related]

  • 4. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE, Deane KH.
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [Abstract] [Full Text] [Related]

  • 5. Cabergoline for levodopa-induced complications in Parkinson's disease.
    Clarke CE, Deane KH.
    Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
    [Abstract] [Full Text] [Related]

  • 6. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH, Spieker S, Clarke CE.
    Cochrane Database Syst Rev; 2004 Oct 18; 2004(4):CD004553. PubMed ID: 15495118
    [Abstract] [Full Text] [Related]

  • 7. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M, Clarke J A.
    Cochrane Database Syst Rev; 2000 Oct 18; 2000(3):CD002259. PubMed ID: 10908539
    [Abstract] [Full Text] [Related]

  • 8. Pramipexole for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M, Clarke J A.
    Cochrane Database Syst Rev; 2000 Oct 18; 2000(3):CD002261. PubMed ID: 10908540
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lisuride for levodopa-induced complications in Parkinson's disease.
    Clarke CE, Speller JM.
    Cochrane Database Syst Rev; 2000 Oct 18; 1999(2):CD001515. PubMed ID: 10796801
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A, Benfield P.
    CNS Drugs; 1997 Apr 18; 7(4):328-40. PubMed ID: 27520755
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Apr 18; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 19. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov 18; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.